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Drug deliveryAbstract In this study,we aimed to improve the anticancer effect of 5-FUonhuman colon cancer cell
lines by incorporating in poly(D,L lactic-co-glycolic acid) (PLGA) nanoparticles (NPs). The 5-FU-
PLGANPs were prepared by nanoprecipitation technique. Prepared NPs were moderately dispersed
with an average diameter of 133 ± 25.19 nm. Scanning ElectronMicroscope (SEM) images revealed
spherical structureswith subtle surface irregularity. Free 5-FUdose–response curveswere constructed
(12.5–2000 lM)usingMTTassay onHCT116 andHT-29 cell lines for 1, 3, and 5 days. The calculated
IC50 onHCT 116were 185 lMafter 1 day, 11.3 lMafter 3 days, and 1.48 lMafter 5 days. OnHT-29,
IC50 was only reached after 5 days of 5-FU treatment (11.25 lM). The HCT 116 viability following
treatment with 100 lM5-FU in free orNPs forms for 3 days was 38.8%and 18.6%, respectively. Sim-
ilarly, when 250 lMwas applied, HCT 116 viability was 17.03% and 14.6% after treatment with free
and NPs forms of 5-FU, respectively. Moreover, HT-29 cell viability after 250 lM5-FU treatment in
free or NPs forms was 55.45% and 34.01%, respectively. We also noticed that HCT 116 cells were
more sensitive to 5-FU-PLGA NPs as compared to HT-29 cells. Overall, our data indicate that
5-FU activity is time dependent and the prolonged effects created by PLGA NPs may contribute,
at least in part, to the noticed enhancement of the anticancer activity of 5-FU drug.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ty, P.O.
y. Saudi
2 E. Tawfik et al.1. Introduction
Colorectal cancer (CRC) has been considered a major health
burden and a leading factor causing mortality and morbidity
worldwide (World Health Organization, 2002). Conventional
CRC chemotherapy provides marginal improvement to
patients (American Cancer Society, 2006). In some cases,
chemotherapy has failed to make significant impact on the
prognosis of disease due to poor bioavailability, poor tissue
selectivity/specificity, and in vivo degradation, which can lead
to serious side effects (Arias, 2008; Nair et al., 2011). More-
over, chemotherapeutics are usually administered in high
doses, which increase the risk of side effects and drug resis-
tance (Duran et al., 2008; Wong et al., 2007; Zamboni et al.,
2012). Thus far, many potent chemotherapeutics have been
developed and extensively studied over the last few decades.
However, insufficient and nonspecific drug delivery remains a
major problem that adversely affects chemotherapeutic anti-
cancer drug efficacy (Gottesman, 2002).
5-Fluorouracil (5-FU) is one of the earliest and still most
commonly used anticancer drugs. Nonetheless, despite its
potency in treating cancers, its clinical applications are limited
due to its short half-life, disease resistance, and severe side
effects such as myelosuppression, dermatitis, cardiotoxicity,
neurotoxicity, nausea, vomiting and gastrointestinal, which is
associated with its high non-specific in vivo distribution
(Blanke et al., 1999; Cai et al., 2006; Cao and Rustum, 2000;
Di Paolo et al., 2001; Fata et al., 1999; Schmoll et al., 1999;
van Kuilenburg et al., 2000). Therefore, it is imperative to
develop a strategy that overcomes the limitations as well as
further improvements in the anticancer response of 5-FU. In
this study, we have utilized polylactic-co-glycolic acid (PLGA)
nanoparticles (NPs) to improve the anticancer activity of 5-FU
in human colon cancer cells.
PLGA is a synthetic copolymer approved by the US FDA
for human use (Jain, 2000). It has been extensively studied as a
carrier for a wide range of drugs including chemotherapeutics
(Lee et al., 2004). In addition to its biodegradability, PLGA is
biocompatible, mechanically strong, soluble in a wide range of
organic solvents, and can be easily processed and fabricated in
various forms and sizes (Avgoustakis, 2004). In aqueous
media, PLGA is hydrolyzed into lactic and glycolic acids that
get consumed in the citric acid cycle and subsequently elimi-
nated as carbon dioxide and water (Jalil and Nixon, 1990).
As a drug carrier, the most widely used PLGA copolymer is
PLGA 50:50 owing to its fastest degradation rate (Park, 1995).
The aim of the current study was to improve the anticancer
effect of 5-FU on human colon cancer cells with the help of
PLGA NPs. For this purpose, 5-FU was loaded on PLGA
(50:50) NPs. In most of the previously published studies,
PLGA NPs were prepared by double-emulsion solvent evapo-
ration method (Li et al., 2008; Parikh et al., 2003; Hu et al.,
2013; Lin et al., 2012; Nair et al., 2011). In this study, we have
explored nanoprecipitation technique for loading of 5-FU on
PLGA NPs. The 5-FU-PLGA NPs complex was further char-
acterized for size, shape, surface charge and size distribution.
Thereafter, we have studied the anticancer effects of 5-FU
loaded PLGA NPs on two types of human colon cancer cell
lines HCT 116 and HT-29. We observed that 5-FU-PLGA
NPs showed higher cytotoxicity to both types of colon cancer
cell line as compared to free 5-FU.Please cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon ca
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2.1. Chemicals and reagents
5-FU, PLGA (50:50 MW 40,000–75,000), poloxamer 188 NF
(Pluronic F-68 NF, MW 8350), and 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, MW 414) were
purchased from Sigma–Aldrich (St. Louis, MO, USA). Human
colon cancer cell lines HCT 116 and HT-29 were bought from
the European Collection of Cell Cultures (ECACC) (Salisbury,
UK). Trypsin-EDTA (0.25%), McCoy’s 5a, Fetal Bovine
Serum (FBS), Penicillin–Streptomycin–Glutamine (100),
and Gentamicin (10 mg/mL) were obtained from Life Tech-
nologies through Salehiya EstPO (Riyadh, Saudi Arabia).
2.2. Preparation of 5-FU-PLGA nanoparticles
5-FU-PLGA NPs were prepared by nanoprecipitation tech-
nique (Barichello et al., 1999). Briefly, 100 mg of PLGA was
dissolved in 10 mL of acetone. This solution was added drop-
wise within 45 s to a stirring solution of 20 mL distilled water
containing 5 mg 5-FU and 200 mg poloxamer 188 and kept on
stirring at 1000 rpm overnight. Then, the formed suspension
was washed three times with double-deionized water at 4 C
at 35,000g for 15 min (Optima MAX-XP Benchtop Ultracen-
trifuge, Brea, CA, USA) and then freeze-dried (LABCONCO
FreeZone 4.5 Liter Benchtop Freeze Dry System, Kansas City,
MO, USA) for 3 days to remove water.
2.3. Characterization of 5-FU-PLGA nanoparticles
2.3.1. Particle size and zeta-potential
The effective diameter and polydispersity index along with zeta
potential were determined by dynamic light scattering using
Nano ZS (Malvern Instruments Ltd., Worcestershire, UK).
In brief, lyophilized 5-FU and 5-FU-PLGA NPs were
re-suspended in 1.5 mL distilled water and poured in a quartz
cuvette. Analysis was performed at ambient temperature with
an angle of detection of 90. Zeta potential was measured by
laser micro-electrophoresis. Similarly, NPs were re-suspended
in 0.5 mL distilled water and added to a folded capillary cell.
The Analysis was performed at ambient temperature with an
applied voltage of 50 V and an applied voltage offset of
0.92 V. Each value represents the average of at least five mea-
surements ± standard deviation (SD).
2.3.2. Surface morphology
Size and surface morphology of dry powder of 5-FU-PLGA
NPs were examined under the scanning electron microscope
SEM EVO LS10 (Carl-Zeiss, Cambridge, UK). Particles were
mounted on double-sided adhesive carbon tape (SPI Supplies,
West Chester, USA) and coated under high-vacuum evaporator
with gold in aQ150R sputter coater unit (QuorumTechnologies
Ltd., East Sussex, UK) in an argon atmosphere at 20 mA for
120 s. The coated samples were scanned, and photomicrographs
were taken at an acceleration voltage of 1–10 kV.
2.3.3. Estimation of 5-FU content on PLGA nanoparticles
5-FU content in 5-FU-PLGA NPs complex was analyzed by
high performance liquid chromatography (HPLC). The HPLCncer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi
Figure 1 Scanning Electron Microscope (SEM) image of 5-FU
loaded on PLGA NPs. (A) Low magnification image and (B) high
magnification image (scale bar 300 nm).
Prolonged exposure of colon cancer cells 3system consisted of an Agilent model connected to HP instru-
ments (Agilent Technologies, Hewlett-Packard-Strasse 8,
Waldbronn, Germany), which contains Agilent Technologies
1200 G1329A ALS autosampler, HP 1100 G1322A degasser,
HP 1100 G1312A bin pump, HP 1100 G1315A diode array
detector, and Agilent ChemStation for LC and LC/MS sys-
tems software. Quantification was achieved by isocratic elution
as described previously (Sun et al., 2007). Mobile phase con-
sisted of phosphate buffer 40 mM (5.44 g Potassium dihydro-
gen orthophosphate (MW 136.09) in 1 L of distilled water
and adjusted to pH 7.2 by 10% (w/v) sodium hydroxide)
and delivered at a flow rate of 1 mL/min at ambient tempera-
ture. C18 guard column (ODS-Hypersil, 5 lm, 20  2.1 mm)
and C18 analytical column (Waters lBondapak C18,
125 A˚, 10 lm, 3.9 mm  150 mm) were used. UV detection
was performed at 260 nm and the injection volume was
90 lL. For standard curve preparation, serial dilution of
5-FU stock solution was performed to obtain 100, 50, 25,
12.5, 6.25, 3.12, 1.56, and 0.78 lg/mL.
To assess 5-FU content on PLGA NP, 1 mL was taken
from the decanted supernatant and 5-FU concentration was
determined by HPLC after plotting a standard curve. Indirect
determination of the entrapment efficiency was attained using
the following equation:
EEð%Þ¼ ½Initial Drug Amount ðmgÞ
UnentrappedDrug Amount ðmgÞ
=ðInitial Drug Amount ðmgÞ100
For direct determination of entrapment efficiency, 5 mg of
5-FU NPs was first dissolved in 50 lL of chloroform. There-
after, chloroform was evaporated at room temperature and
then 500 lL of distilled water was added to the precipitant
and mixed by vigorous vortexing for 30 min to dissolve the
precipitated 5-FU but not PLGA. After that, the formed sus-
pension was centrifuged by SpectrafugeTM 24D centrifuge (Lab-
net International, Inc., Edison, NJ, USA) at 5000 rpm for
3 min at 25 C. The 5-FU content was determined by HPLC
after plotting a standard curve and the entrapment efficiency
was determined by the following equation:
EEð%Þ ¼ ½Entrapped Drug Amount ðmgÞ
=ðInitial Drug Amount ðmgÞ  100
The method of extracting 5-FU from PLGA NPs was val-
idated by the following spike study: 5 mg of PLGA NPs was
spiked with 0.5 mL of 5-FU solution containing 0.25 mg drug
and gently vortexed for 5 s. The sample was kept at room tem-
perature for 6 h until completely dried. Then 50 lL of chloro-
form was used to completely dissolve the NPs and then was left
for 4 h to evaporate. Thereafter, 0.5 mL of water was mixed by
vigorous vortexing for 30 min. After that, the formed suspen-
sion was centrifuged by SpectrafugeTM 24D centrifuge (Labnet
International, Inc., Edison, NJ, USA) for 3 min at 5000 rpm at
25 C. The 5-FU content was determined by HPLC after plot-
ting a standard curve. The recovery was around 99%.
Percentage of drug loading (DL%) was also calculated
using the following equation:
DLð%Þ¼ ½Amount of Drug in NP ðmgÞ
=ðAmount of Drug in NP ðmgÞ
þAmount of Drug in Excipients Added ðmgÞÞ100Please cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon can
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nanoparticles
Aliquots of 5 mg/mL of the suspended 5-FU-PLGA NPs in
PBS were placed in a shaking water bath at 37 C for 45 days.
At designated time intervals, a set of triplicate samples was
removed, and the supernatant was separated from the particles
by centrifugation. Determination of 5-FU concentrations was
conducted by HPLC as mentioned earlier.
2.4. Cell culture and nanoparticles treatment
Human colon cancer cell lines, HCT 116 and HT-29 were used
to assess the cytotoxicity of 5-FU and 5FU-PLGA NPs. Each
cell line was propagated in the designated medium and pas-
saged according to ECACC recommendation. Cells were cul-
tured in McCoy’s 5a medium supplemented with 10% FBS,
1% penicillin-streptomycin and 1% gentamicin at 5% CO2
and 37 C. At 85% confluence, cells were harvested using
0.25% trypsin and were sub-cultured into 25 cm2 flasks or
48-well plates according to selection of experiments. Cells were
allowed to attach the surface for 24 h prior to NPs exposure.cer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi
Figure 2 Cumulative in vitro release of 5-FU from PLGA NPs.
In vitro release profile of 5-FU in PBS detected over 45 days. Data
represented are mean ± SD of three identical experiments made in
three replicate.
4 E. Tawfik et al.Dry powder of 5-FU and 5-FU-PLGA NPs was suspended
in cell culture medium at a concentration of 100 mM and
diluted to appropriate concentrations according to selection
of experiments. The dilutions of NPs were then sonicated using
a sonicator bath at room temperature for 15 min at 40 W to
avoid NPs agglomeration prior to cell exposure. Cells not
exposed to NPs served as controls in each experiment.
2.5. Cytotoxicity assay
Cytotoxicity of 5-FU and 5-FU-PLGA NPs in HCT 116 and
HT-29 cells was examined by MTT cell proliferation assay.
This assay assesses the mitochondrial function by measuring
ability of viable cells to reduce MTT into blue formazon prod-
uct. In brief, 7  104 cells/well were seeded in 48-well plates
and exposed to different concentrations of NPs for 24, 72
and 120 h. At the end of the exposure time, culture medium
was removed from each well to avoid interference of NPs
and replaced with new medium containing MTT solution in
an amount equal to 10% of culture volume and incubated in
CO2 incubator (SANYO Electric Biomedical Co., Ltd.,
Osaka, Japan) for 2–4 h at 37 C until a purple-colored for-
mazan product developed. The formed purple formazan crys-
tals were solubilized by the addition of equal volume of
isopropanol to each well and gentle shaking for 30 min. Color
intensity was then measured by a microplate spectrophotome-
ter (BioTek Instruments, Inc., Winooski, VT, USA) at 570 nm
and percentage cell viability was calculated relative to
untreated cells group. The results represent mean ± SD of at
least three replicates.
2.6. Statistical analysis
Statistical analysis of obtained results was done by one-way
analysis of variance (ANOVA) using IBM SPSS statistics
22.0 software. P< 0.05 was taken as a criterion for a statisti-
cally significant difference.
3. Results and discussion
This work aims to improve single-dose effect of 5-FU anti-
cancer drug on human colon cancer cells. For this purpose,
5-FU was entrapped in PLGA NPs and treated to HCT 116
and HT-29 cell lines in order to assess its in vitro cytotoxicity.
3.1. Characterization of 5-FU-PLGA nanoparticles
The 5-FU-loaded PLGA NPs showed a mean particle diameter
of 133 ± 25.19 nm. When compared to the mean diameter of
empty PLGA NPs (117.9 ± 21.53 nm), the size of 5-FU-
PLGA NPs was slightly increased. Although no statistical sig-
nificance was determined when both means were compared,
the observed increment in the mean particle diameter of the
5-FU-loaded PLGA NPs can be attributed to successful
entrapment of the drug. These observations are consistent with
the work of Kumar and his colleagues, who used double-
emulsion solvent evaporation technique to encapsulate 5-FU
(Nair et al., 2011). The authors reported 135 nm mean
diameter of empty PLGA NPs and 150 nm after 5-FU
encapsulation. Our SEM images revealed spherical structures
of 5-FU-PLGA NPs with slight surface irregularity (Fig. 1A).Please cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon ca
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.010During nano-precipitation, hydrophobic polymers are driven
to self-assemble into spherical or irregular nanoparticles
as a result of the quick transfer from good-solvent to poor-
solvent conditions (Hornig et al., 2009). Since this method is
not emulsion-based, the relatively quick precipitation of
PLGA contributed to the irregularity of the formed spherical
shape. Nonetheless, 5-FU NPs were produced with measured
polydispersity index of 0.352 indicating moderate dispersity,
which is inferred by the SEM image (Fig. 1B).
3.2. Determination of 5-FU content
HPLC assay, reported in (Alanazi et al., 2009) was utilized to
quantify 5-FU entrapment within PLGA NPs (direct method)
as well as un-entrapped 5-FU recovered in the supernatant
after PLGA NPs preparation (indirect method). 5-FU content
was calculated from standard curve. Direct and indirect assess-
ments were consistent and showed EE% of 40% and DL%
of 7%. This entrapped amount, although can be possibly
increased, was found sufficient to exert cytotoxic action. This
can be attributed to the choice of PLGA NPs preparation tech-
nique. We chose nanoprecipitation because of the physico-
chemical properties of 5-FU. Owing to its solubility profile
(sparingly soluble) as well as low affinity to PLGA, nanopre-
cipitation was thought to improve 5-FU EE% in PLGA
NPs. Very few reports have explored this technique for 5-FU
loading in PLGA NPs (Karmi et al., 2011; Ashwanikumar
et al., 2014).
3.3. In vitro release study
The cumulative release of 5-FU was following classical tripha-
sic release profile of PLGA NPs (Fig. 2). Initial burst release
was documented reaching 12% in the first 6 h, 16% after
12 h, and 22% after 24 h. Thereafter, 60% of 5-FU was
sustain-released over the next two weeks. Another climb in
5-FU level was noticed as a result of polymer degradation
reaching 80% by day 20 of the study. The rest 20% was then
slowly released over the next two weeks. The prolonged releasencer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi
Figure 3 Cytotoxicity of 5-FU in HCT 116 cells. Cells were exposed to different concentrations of 5-FU for different time intervals. At
the end of the exposure, MTT cell viability was determined as described in materials and methods. (A) 1-day exposure, (B) 3-day exposure
and (C) 5-day exposure time. Data represented are mean ± SD of three identical experiments made in three replicate.
Prolonged exposure of colon cancer cells 5of 5-FU, 45 days, is primarily due to the high molecular weight
of PLGA used in this formulation (Shive and Anderson, 1997).
However, it is worth noting that PLGA NPs degradation pat-
tern may remarkably vary following cellular uptake and,
hence, 5-FU release and pharmacological onset.
3.4. Determination of cytotoxicity of 5-FU and 5-FU-PLGA
nanoparticles
We evaluated the cytotoxic ability of free 5-FU and 5-FU-
PLGA NPs against two human colon cancer cell lines (HCT
116 and HT-29). These cell lines were chosen based on their
p53-expression profile: wild type in the case of HCT 116 and
mutant in HT-29. Dose–response curves were constructed for
free 5-FU in concentration range (12.5–2000 lM) against rela-
tive cell viability percentage of HCT 116 cells (Fig. 3) and HT-
29 cells (Fig. 4) and for 1, 3, and 5 days. Results showed that
both types of colon cells responded to the cytotoxic effect of
free 5-FU in dose-dependent and time-dependent manner. In
spite of the observed dose dependency, the time factor demon-
strated more influence on 5-FU activity (Table 1). The calcu-
lated IC50 of 5-FU after 1 day exposure to HCT 116 wasPlease cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon can
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.010around 185 lM (Fig. 3A). A remarkably lower concentration,
11.3 lM, was needed to reduce cell viability to 50% after
3 days of single-dose exposure (Fig. 3B). Furthermore, approx-
imately 1.48 lM of 5-FU was sufficient to reduce 50% cell
viability after 5 days of exposure (Fig. 3C). Similarly, the
time-dependent response was more palpable in the case of
HT-29 than mere increment of 5-FU concentration. While
no IC50 was reached after 1 day or 3 days of 5-FU treatment
at any concentration (Fig. 3A and B), the cytotoxic effect
was profound (IC50 equals 11.25 lM) after 5 days of initial
treatment (Fig. 4C).
These observations indicate that the cytotoxic effect of
5-FU is more dependent on prolonged exposure to cells rather
than availability of higher concentration with short cell expo-
sure. Recently, Han and colleagues (Sui et al., 2014) reported
that autophagy is activated in a time-dependent manner in
5-FU-treated HCT 116 and HT-29 cells. Moreover, the
aberrant expression of p-53 is thought to abrogate 5-FU ability
to induce p53-dependent cell growth arrest and apoptosis. This
was supported by the fact that HCT 116 p53/ cells were less
responsive than their p53+/+ counterparts (Sui et al., 2014).
Hence, p53 deletion or mutation can induce resistance tocer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi
Figure 4 Cytotoxicity of 5-FU in HT-29 cells. Cells were exposed to different concentrations of 5-FU for different time intervals. At the
end of the exposure, MTT cell viability was determined as described in materials and methods. (A) 1-day exposure, (B) 3-day exposure and
(C) 5-day exposure time. Data represented are mean ± SD of three identical experiments made in three replicate.
Table 1 IC50 values of 5-FU for colon cancer cells.
Colon cancer cell line IC50 values (lM)
1 day 3 day 5 day
HCT 116 185 13.5 1.48
HT-29 Not reached Not reached 11.25
6 E. Tawfik et al.5-FU (Subbarayan et al., 2010; Huang et al., 2009; Sun et al.,
2007). Interestingly, the IC50 calculated after 5 days of treat-
ment in case of HT-29 cells (11.25 lM) was approximately
similar to that of HCT 116 after 3 days of 5-FU treatment
(11.3 lM). Given that HT-29 cells are less sensitive to 5-FU
treatment, this further indicates that prolonged 5-FU exposure
enhances the desired cytotoxicity. Therefore, we next
explored whether PLGA NPs can enhance the cytotoxic
effect of 5-FU.
HCT 116 or HT-29 cells were incubated with 5-FU, 5-FU-
PLGA NPs, or empty PLGA NPs for 3 days. Thereafter, cell
viability was determined by MTT assay. As shown in Fig. 5A,Please cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon ca
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.010applying 100 lM 5-FU in free or NPs forms on HCT 116 cells
resulted in significant inhibition of cell viability reaching
38.8% and 18.6%, respectively. Similarly, when 250 lM was
applied, both free and NPs forms of 5-FU demonstrated sig-
nificant reduction in cell viability with marginal advantage of
5-FU-PLGA NPs (14.6%) over the free 5-FU (17.03%). How-
ever, no statistical significance was noticed at this concentra-
tion. A slight reduction in cell viability was also recorded
with empty PLGA NPs (91.3%) when used in an amount
equivalent to the amount containing 250 lM 5-FU. Nonethe-
less, this reduction in cell viability was not statistically signifi-
cant when compared to untreated cells.
In HT-29 cells, only 250 lM concentration was used in the
cytotoxicity assay. The recorded cell viability with 5-FU NPs
was 34.01%, while the cell viability recorded with free 5-FU
was 55.45% (Fig. 5B). Beside the significant advantage of 5-
FU NPs, it was not possible for us to reduce HT-29 cell viabil-
ity with 5-FU below 50% except when formulated in PLGA
NPs. This observation suggests that the PLGA NPs not only
retained but also improved the single-dose effect of 5-FU on
human colon cancer cell lines. Our results are consistent withncer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi
Figure 5 Cytotoxicity of 5-FU and 5-FU-PLGA NPs in HCT
116 and HT-29 cells. Cells were exposed to 100 lM (black bars) or
250 lM (gray bars) of 5-FU and 5-FU-PLGA NPs. At the end of
the exposure, MTT cell viability was determined as described in
materials and methods. (A) HCT 116 cells and (B) HT-29 cells.
Data represented are mean ± SD of three identical experiments
made in three replicate. *Significant difference between 5-FU and
5-FU-PLGA NPs exposure (p< 0.05 for each).
Prolonged exposure of colon cancer cells 7others work where superiority of 5-FU-loaded NPs has been
reported in different cancer cell lines (Wang et al., 2015; Ali
et al., 2011; Nair et al., 2011). We attribute this to the pro-
longed drug exposure provided by the PLGA system as well
as possible evasion of inactivation mechanisms such as intra-
cellular degradation. This is still to be investigated. We did
not investigate the cytotoxicity of 5-FU-PLGA NPs on non-
cancerous cell lines. We will explore the mechanisms of anti-
cancer activity of 5-FU-PLGA NPs and their biocompatibility
to non-cancerous cells in future studies.
4. Conclusions
We have made progress toward developing PLGA NPs for
5-FU delivery by nano-precipitation technique. Our data
showed that 5-FU cytotoxicity to colon cell lines is likely to
be more influenced by the treatment time rather than dose
escalation. We also demonstrated that PLGA-based NPs can
aid in improving the anticancer activity of 5-FU and reducingPlease cite this article in press as: Tawfik, E. et al., Prolonged exposure of colon can
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.010the exposure time needed to reach similar effect with free 5-
FU. Furthermore, the superiority of 5-FU-PLGA NPs over
free 5-FU was consistent even with a more resistant cell line.
Nevertheless, further mechanistic investigations are still
required to understand the enhancing effect of PLGA NPs
on 5-FU anticancer activity.Acknowledgment
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